Less than seven weeks after the Food and Drug Administration issued its most serious possible product warning, the Target Up & Up baby wipes lawsuit is rapidly expanding from a single personal injury filing into a multi-front federal litigation with nearly 7 million contaminated packages at its center. Two bacterial strains capable of causing sepsis, pneumonia, and death in newborns were found in wipes marketed as gentle, hypoallergenic, and “99% water” — and evidence is already surfacing that complaints were received before the June 4, 2026 recall was ever issued. If you purchased Up & Up baby wipes or your child was harmed, here is everything you need to know right now.
The June 4, 2026 FDA Class I Recall: What Was Found and Why It Matters
On June 4, 2026, Target Corporation voluntarily recalled two lines of its Up & Up store-brand baby wipes after consumer complaints about product discoloration triggered FDA laboratory testing. That testing confirmed the presence of Burkholderia cepacia complex and Burkholderia gladioli — two dangerous bacterial pathogens — in the wipes. The FDA formally published its recall notice and assigned the action a Class I classification, the agency’s highest risk tier, reserved for situations involving a reasonable probability that use of the product will cause serious adverse health consequences or death. The recall ultimately covered 6,845,936 packages of Up & Up baby wipes — one of the largest baby product recalls in recent memory.
Burkholderia cepacia complex is particularly dangerous for newborns, infants, and immunocompromised individuals. The bacteria can penetrate the bloodstream through even microscopic breaks in skin — the type of minor skin irritation that diaper rash routinely causes — and produce life-threatening sepsis or pneumonia. For healthy adults, exposure may cause mild or no symptoms. For a two-week-old infant, it can mean an ICU admission. The CDC recognizes Burkholderia cepacia complex as an established cause of severe, difficult-to-treat infections, particularly in vulnerable patient populations.
The affected products were manufactured by Turkish company Sapro Temizlik Urunleri and span two product lines with manufacturing date windows now confirmed by Target’s own recall notice. Critically, both Target and Sapro Temizlik Urunleri had received consumer complaints and adverse event reports prior to the June 4, 2026 recall being issued — a fact that is now central to the litigation unfolding in federal courts. Families who used these wipes on newborns or immunocompromised household members face the highest injury exposure in the Target Up & Up baby wipes lawsuit landscape.
Recall Scope: Affected SKUs, Dates, and Stores
The recall covers 6,845,936 packages sold at Target retail locations and Target.com nationwide. Understanding exactly which products are included is essential for any family considering legal action or seeking a refund.
| Product Name | Package Sizes Recalled | Manufacturing Date Range | Distribution |
|---|---|---|---|
| Up & Up Fragrance Free Baby Wipes | 20, 72, 216, 800, 1,200 count | November 7, 2025 – May 5, 2026 | Target stores & Target.com, nationwide |
| Up & Up Fresh Cucumber Baby Wipes | 72, 216, 800 count | November 7, 2025 – May 5, 2026 | Target stores & Target.com, nationwide |
Consumers who purchased any of these products during the manufacturing window should immediately stop using them, safely dispose of the packages, and retain any documentation of the purchase. Target has stated that refunds are available without a receipt, but families who suffered a child’s injury should consult an attorney before simply returning the product, as doing so without documentation may complicate a future legal claim.
The Lawsuits Filed So Far: A Litigation Timeline
The legal response to the June 4, 2026 recall has been swift. Within weeks of the FDA’s announcement, multiple lawsuits were filed across federal courts, and the litigation landscape continues to evolve. As of mid-2026, no case has reached settlement or final judgment — these matters are in their earliest procedural stages, but the volume and speed of filings signal that this litigation will grow significantly.
June 22, 2026 — First Personal Injury Suit: Baby W.G. and the Goldfin Family
The first known lawsuit arising from the recall was filed on June 22, 2026, less than three weeks after the FDA recall notice. The plaintiffs, identified as the Goldfin family, filed suit on behalf of their infant child, referred to in court documents as Baby W.G. The complaint alleges that Baby W.G. suffered a documented bacterial infection consistent with Burkholderia exposure after being wiped with recalled Up & Up products during the newborn period. The family’s claims include strict products liability, negligence, and failure to warn. This filing established the initial personal injury template that subsequent attorneys have adapted for their own clients.
July 2, 2026 — First Federal Class Action: Northern District of Illinois
On July 2, 2026, plaintiffs Finek and O’Neal filed the first federal class action lawsuit in the Northern District of Illinois — home to Target’s significant Midwest consumer base and a venue with an established mass tort docket. The complaint names both Target Corporation and manufacturer Sapro Temizlik Urunleri as defendants. A central allegation in this filing goes beyond simple product defect: the plaintiffs assert that Target continued selling contaminated wipes despite knowing of the contamination — and that both Target and Sapro had received consumer complaints and adverse event reports well before the June 4, 2026 recall was announced. If that timeline of knowledge is proven, it could dramatically increase defendants’ exposure to punitive damages beyond compensatory losses. This lawsuit seeks class certification on behalf of all U.S. consumers who purchased the recalled products.
July 8, 2026 — Second Federal Class Action: New York
A second class action was filed in the Eastern District of New York on July 8, 2026, broadening the geographic scope of the litigation. This complaint largely mirrors the Illinois filing in its core allegations but emphasizes New York consumer protection law claims alongside federal products liability theories. The New York filing also raises an issue that legal observers expect to become increasingly prominent across the baby wipes litigation landscape: the presence of undisclosed PFAS chemicals and microplastics in major wipe brands beyond the specific products covered by Target’s bacterial recall. This parallel litigation wave — targeting multiple manufacturers — suggests that the Target recall may be the visible tip of a much larger set of product safety concerns in the baby wipes category.
The ‘Deliberately Inadequate Recall’ Allegation — A Core Legal Theory
Among the most legally significant claims threading through the Target Up & Up baby wipes lawsuits is what attorneys have characterized as a deliberately inadequate or delayed recall. This theory holds that Target and Sapro Temizlik Urunleri possessed information — through consumer complaints and adverse event reports — sufficient to alert them to a contamination problem before the June 4, 2026 recall date, yet continued to sell the products.
In products liability law, the timing of a manufacturer’s or retailer’s knowledge is critical. When a company continues to sell a product it has reason to believe is dangerous, the legal exposure shifts from ordinary negligence into territory that can support claims of gross negligence, reckless disregard for consumer safety, and — in some jurisdictions — punitive damages. Punitive damages are designed not to compensate victims but to punish egregious corporate conduct and deter future misconduct. They can multiply a verdict’s value far beyond actual medical costs and economic losses.
The Illinois class action filed by Finek and O’Neal on June 12, 2026 places this theory at the center of its complaint. Plaintiffs’ counsel will spend the coming months in discovery attempting to establish the precise date on which Target and Sapro first received credible information suggesting contamination — and comparing that date to the date the recall was issued. Internal communications, quality control records, consumer complaint logs, and adverse event databases will all be subpoenaed. How that evidence develops will largely determine whether this litigation ultimately resolves through individual settlements, a global class settlement, or trial verdicts.
Who Is at Risk: Injury Exposure and Medical Harms
Not every person who purchased recalled Up & Up baby wipes will have a viable personal injury claim, but the range of potential plaintiffs is wide. Legal exposure in this litigation is generally grouped into three tiers based on the nature and severity of documented harm.
Highest Exposure — Documented Bacterial Infection in Infants: Newborns and young infants who developed Burkholderia cepacia complex or Burkholderia gladioli infections during the period covered by the recall, and whose families can link wipe use to that diagnosis, represent the strongest individual personal injury claims. These cases involve the most serious medical harms — sepsis, pneumonia, extended NICU or ICU hospitalization, long-term respiratory complications, and, in the most tragic circumstances, infant death. Damages in these cases can include past and future medical expenses, pain and suffering, and in wrongful death cases, loss of companionship claims by parents.
Moderate Exposure — Unexplained Illness During Wipe Use: Infants or immunocompromised individuals who experienced unexplained infections, respiratory illness, or skin infections during the recall period but were not specifically tested for Burkholderia may still have viable claims, particularly if medical records document the timing and nature of the illness. Retrospective laboratory confirmation may not always be possible, but circumstantial evidence of causation combined with the known contamination can be sufficient to support a claim in many jurisdictions.
Consumer Class Claims — Economic Loss Without Physical Injury: Parents and caregivers who purchased recalled products but whose children did not become visibly ill still have potential claims for economic loss — the purchase price of contaminated products sold under false pretenses of safety. These claims form the basis of the class action lawsuits already filed in Illinois and New York. While individual recovery in a consumer class action is typically modest, the aggregate value of claims across millions of recalled packages is substantial.
A concurrent and growing litigation wave also alleges that baby wipes across multiple major brands — not just Target’s recalled lines — contain undisclosed PFAS chemicals and microplastics. Families who used wipes from other manufacturers during this same period may find they have exposure to this parallel litigation track as it develops through 2026 and beyond.
What Affected Families Should Do Right Now
The actions taken in the weeks and months immediately following a product recall can significantly affect the strength of any future legal claim. Families who purchased recalled Up & Up baby wipes — or who believe their child was harmed — should take the following steps promptly.
Stop using the product immediately and set the packages aside in a safe location. Do not throw them away. The physical product, including the lot number printed on the packaging, is evidence. If your child was harmed, that packaging may be tested as part of your legal case.
Gather all documentation of purchase. Target app purchase history, credit card or bank statements showing Target transactions, Target Circle rewards records, and online order confirmations all constitute proof of purchase. Even without a receipt, these records can establish that you purchased the product during the recall window.
Seek medical evaluation immediately if your child experienced any symptoms that could be consistent with bacterial infection — unexplained fever, respiratory distress, unusual skin irritation or infection, or lethargy — particularly during the November 2025 through May 2026 period when contaminated products were on shelves. Ask your pediatrician to document the visit, the symptoms, and any relevant testing. If your child was previously hospitalized during this period for unexplained infection, obtain those medical records now.
Do not contact Target or Sapro directly for anything beyond a basic product refund until you have consulted an attorney. Statements you make to corporate representatives or their insurers can be used against your claim. If you have already filed a complaint with Target’s consumer line or submitted an adverse event report to the FDA, document what you said and when.
Consult a mass tort attorney promptly. Statutes of limitations — the legal deadlines for filing personal injury claims — vary by state and begin running from the date of injury or the date a plaintiff reasonably should have discovered the connection between the product and the harm. With the recall publicly announced in June 2026, the clock is already running. Many mass tort attorneys handling these cases offer free consultations and work on contingency, meaning no upfront legal fees.
Frequently Asked Questions About the Target Up & Up Baby Wipes Lawsuit
What bacteria were found in the recalled Target Up & Up baby wipes, and how dangerous are they?
FDA laboratory testing confirmed the presence of two related bacterial pathogens: Burkholderia cepacia complex and Burkholderia gladioli. Both belong to a group of gram-negative bacteria that are particularly hazardous to newborns, infants, and immunocompromised individuals. Burkholderia cepacia complex is recognized by the CDC as a leading cause of severe respiratory infections and bloodstream infections in vulnerable populations. These bacteria are naturally resistant to many common antibiotics, making infections difficult to treat and increasing the risk of fatal outcomes. For a healthy adult, skin contact with these bacteria may cause no symptoms at all. For a premature infant or a newborn with compromised skin integrity from diaper rash or eczema, exposure can result in sepsis, pneumonia, or death. The FDA’s Class I recall designation — its most serious tier — reflects this life-threatening risk profile.
Which Target Up & Up baby wipes are included in the recall?
The June 4, 2026 recall covers two product lines manufactured by Sapro Temizlik Urunleri: Up & Up Fragrance Free Baby Wipes and Up & Up Fresh Cucumber Baby Wipes, in multiple package sizes ranging from 20-count to 1,200-count packages, with manufacturing dates between November 7, 2025 and May 5, 2026. The recall applies to products sold at all Target retail stores and on Target.com across the United States and encompasses 6,845,936 packages in total. Lot numbers and UPC codes for all affected SKUs are listed on the FDA’s recall database and Target’s corporate recall page. If you have packaging from this period, check the manufacturing date printed on the bottom or back of the package against the recall window before discarding anything.
Can I still file a lawsuit if I don’t have my receipt or the original product packaging?
Yes, in most cases. Receipt and packaging are helpful evidence, but they are not absolute prerequisites for a legal claim. Target maintains detailed purchase records tied to its Target Circle loyalty program and guest checkout records linked to payment methods. Bank and credit card statements showing Target purchases during the relevant period can help establish that you bought the product. For personal injury claims specifically, medical records documenting the timing and nature of your child’s illness may be sufficient to proceed even if product documentation is incomplete. An experienced mass tort attorney can assess what evidence you have and advise on the strength of your claim. Do not assume you have no case simply because you no longer have the package or a receipt.
What is the current status of the Target Up & Up baby wipes lawsuits and is there an MDL?
As of June 2026, the litigation is in its earliest stages. Multiple lawsuits have been filed — including at least one personal injury case on behalf of an injured infant and two federal class actions in Illinois and New York — but no case has reached settlement or final judgment. There is no Multidistrict Litigation (MDL) consolidation order in place as of this writing, though the volume and geographic spread of filings make MDL consolidation a realistic near-term development if additional cases continue to be filed across multiple federal districts. Attorneys working in this space are monitoring docket activity closely. The coming months will see initial scheduling orders, early discovery disputes over corporate documents, and likely motions by defendants to dismiss or limit certain claims. Families who believe they have a claim should not wait for an MDL to form before consulting an attorney, as early retention preserves evidence and ensures compliance with applicable statutes of limitations.
Who are the defendants in the Target Up & Up baby wipes lawsuits and what are the claims?
The primary defendants named across the filed lawsuits are Target Corporation, as the retailer and brand owner of the Up & Up product line, and Sapro Temizlik Urunleri, the Turkish manufacturer that produced the contaminated wipes. Claims asserted across the various filings include strict products liability for manufacturing defect, negligence in quality control and testing, failure to warn consumers of known contamination risks, breach of implied warranty of merchantability, and violations of state consumer protection statutes. The class actions also assert unjust enrichment — the theory that Target and Sapro profited from selling a product that was unfit for its intended purpose. A particularly significant legal theory in the Illinois class action filed by Finek and O’Neal is that Target continued selling contaminated products despite prior knowledge of the contamination, based on consumer complaints and adverse event reports received before the June 4, 2026 recall. If discovery substantiates that timeline, it could open the door to punitive damages claims that substantially increase defendants’ total financial exposure beyond compensatory losses alone.
Victoria Chambers is a mass tort and class action research analyst with extensive knowledge of multi-district litigation (MDL), defective product cases, dangerous drug lawsuits, and toxic exposure claims across the United States. Victoria is not an attorney and the information provided is for educational purposes only.